Tumor-Activated Anti-CTLA-4 Conjugate for Lower Autoimmune Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune checkpoint antibodies like CTLA-4 and PD-1, while effective in treating tumors, cause non-specific T cell activation leading to immune-related adverse events (irAEs) and autoimmune toxicity in normal tissues, limiting their response rate and safety.
Innovation Solution
A conjugate of an anti-CTLA-4 antibody modified with cysteine mutations and a functional group (R1-R2-R3-L-R4) that is activated only in the tumor microenvironment by proteases and acidic conditions, maintaining or enhancing antigen binding after cleavage, reducing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint antibodies (CTLA-4, PD-1) are used to remove inhibitory signaling pathways of T cells, then anti-tumor immune response is enhanced, but non-specific activation of T cells in non-tumor target organs occurs leading to immune-related adverse events (irAEs)
Solution Approach 1:
The patent applies local quality by creating an antibody conjugate with a tumor microenvironment-responsive linker that enables the antibody to exert its immune-enhancing effect specifically at the tumor site while remaining inactive in normal tissues. The linker contains acid-labile bonds and protease-sensitive sequences that are only cleaved in the acidic tumor microenvironment, allowing localized T cell activation without systemic autoimmune toxicity.
Solution Approach 2:
The patent uses the tumor microenvironment itself as an intermediary through its unique acidic pH and protease presence to trigger activation of the conjugate. The acidic conditions and proteases in the tumor microenvironment cleave the linker, releasing the functional antibody only where needed, thus mediating between systemic administration and localized effect.
2Reliability
If combined immunotherapy with PD-1 and CTLA-4 antibodies is used to improve response rate, then overall response rate increases from 20-30% to 58%, but the incidence of serious treatment-related adverse events (grade 3-4) increases from 16-27% to 55%
Solution Approach 1:
The patent applies local quality by designing a conjugate that concentrates the immune-enhancing effect at the tumor site through tumor microenvironment-responsive activation. This localized action allows combined immunotherapy effects to be achieved with reduced systemic exposure, thereby maintaining high response rates while minimizing serious adverse events in normal organs.
Solution Approach 2:
The patent segments the antibody function from its activation state by using a prodrug-like conjugate structure. The antibody is delivered in an inactive blocked state systemically, then activated only at the tumor site through linker cleavage by acidic conditions and proteases, effectively segmenting the therapeutic effect from systemic exposure.
3Reliability
If CTLA-4 antibodies with Fc effector functions are used to eliminate Treg cells through ADCC effects, then suppressive microenvironment of tumor is eliminated and anti-tumor immune response is enhanced, but autoimmune reactions in normal organs are promoted leading to irAEs
Solution Approach 1:
The patent applies local quality by ensuring that the Fc effector functions and ADCC activity are only activated at the tumor site through microenvironment-responsive linker cleavage. The conjugate remains inactive in circulation, preventing systemic Treg cell elimination and autoimmune reactions, while exerting strong local effects in the tumor microenvironment where acidic conditions and proteases trigger activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate selectively targets tumor sites, enhancing anti-tumor immune response while minimizing autoimmune toxicity in normal tissues, improving treatment efficacy and reducing systemic side effects.
Implementation Method 1
R2 is a linker that can be hydrolyzed and cleaved by one or more proteases in the pathological microenvironment
Implementation Method 2
L is a chemical bond activated under acidic conditions in the pathological microenvironment
Implementation Method 3
R4 is a group covalently linked to R5 through the sulfur atom on cysteine in R5
Data Source
AI summary
A conjugate of an anti-CTLA-4 antibody activated by a tumor microenvironment and an application thereof. The conjugate has the following structure: R1-R2-R3-L-R4-S-cys-R5, wherein R1, R2, R3, L, R4, and R5 each represent structures such as different functional groups, linkers, chemical bonds, and CTLA-4 antibodies. The conjugate is a dual-activated conjugate, which can improve the targeting efficacy of the anti-CTLA-4 antibody while overcoming the drug resistance of the antibody and reducing toxicity.